GELITA Presents Latest Osteoarthritis Research Findings at FIE

Thanks to its excellent product properties like neutral taste and odour FORTIGEL is easy to integrate into a wide range of application and the positive health aspects can be achieved even with low doses.

23 Oct 2009 ---  The administration of FORTIGEL from Gelita can prevent joint degeneration and counteract load-induced wear of the articular cartilage. Unlike other substances which focus on short-term pain relief, FORTIGEL measurably improves joint health by tackling the root causes of osteoarthritis and cartilage degeneration.

Results of two independent investigations were presented at the recent world congress of the Osteoarthritis Research Society International (OARSI) in Montreal. A clinical trial performed by Harvard Medical School and Tufts Medical Center demonstrated the efficacy of FORTIGEL on the basis of magnetic resonance images (MRI) while cell experiments conducted at the Kiel-based Collagen Research Institute (CRI) indicated that FORTIGEL induces the increased synthesis of aggrecan (an important component in cartilage) and Type II collagen (which plays a key role in cartilage elasticity). Both studies confirmed:

Thanks to its excellent product properties like neutral taste and odour FORTIGEL is easy to integrate into a wide range of application and the positive health aspects can be achieved even with low doses.

GELITA (8L23) will exhibit at FI Europe from November 17 – 19 in Frankfurt. A number of product examples such as beverages and yogurt drinks will be served at the GELITA booth.